Log in

NASDAQ:INMDInMode Stock Price, Forecast & News

-0.06 (-0.18 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $33.91
50-Day Range
MA: $25.69
52-Week Range
Now: $33.91
Volume1.09 million shs
Average Volume906,066 shs
Market Capitalization$1.08 billion
P/E Ratio22.91
Dividend YieldN/A
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:INMD



Sales & Book Value

Annual Sales$156.36 million
Cash Flow$1.92 per share
Book Value$5.62 per share


Net Income$61.15 million


Market Cap$1.08 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

InMode (NASDAQ:INMD) Frequently Asked Questions

How has InMode's stock been impacted by COVID-19 (Coronavirus)?

InMode's stock was trading at $24.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INMD stock has increased by 39.0% and is now trading at $33.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of InMode?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMode.

When is InMode's next earnings date?

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for InMode.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) posted its earnings results on Wednesday, May, 6th. The healthcare company reported $0.30 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.32 by $0.02. The healthcare company earned $40.44 million during the quarter, compared to analysts' expectations of $38.96 million. InMode had a net margin of 34.56% and a return on equity of 37.88%. The company's revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share. View InMode's earnings history.

What price target have analysts set for INMD?

4 analysts have issued twelve-month price targets for InMode's stock. Their forecasts range from $36.00 to $55.00. On average, they anticipate InMode's stock price to reach $43.25 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View analysts' price targets for InMode.

Has InMode been receiving favorable news coverage?

Media coverage about INMD stock has been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. InMode earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutInMode.

Are investors shorting InMode?

InMode saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, a decrease of 29.9% from the April 30th total of 2,240,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 1.1 days. Currently, 11.4% of the company's stock are short sold. View InMode's Current Options Chain.

Who are some of InMode's key competitors?

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM), Trade Desk (TTD), AbbVie (ABBV), Alteryx (AYX), Micron Technology (MU), Okta (OKTA) and Square (SQ).

Who are InMode's key executives?

InMode's management team includes the following people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
  • Mr. Yair Malca, Chief Financial Officer (Age 41)
  • Dr. Michael Kreindel, CTO & Director (Age 51)
  • Mr. Shakil Lakhani, Pres of North America (Age 35)
  • Dr. Spero Theodorou, Chief Medical Officer (Age 47)

When did InMode IPO?

(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors Inc. (1.31%), Avalon Investment & Advisory (0.41%), Morgan Stanley (0.40%), Morgan Stanley (0.40%), UBS Group AG (0.31%) and Two Sigma Investments LP (0.29%).

Which institutional investors are selling InMode stock?

INMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Wells Fargo & Company MN, Mackenzie Financial Corp, UBS Group AG, JPMorgan Chase & Co., Steward Partners Investment Advisory LLC, and Fred Alger Management LLC.

Which institutional investors are buying InMode stock?

INMD stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Two Sigma Investments LP, Axel Capital Management LLC, Avalon Investment & Advisory, Telemus Capital LLC, Roubaix Capital LLC, Federated Hermes Inc., and Geode Capital Management LLC.

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $33.91.

How big of a company is InMode?

InMode has a market capitalization of $1.08 billion and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

What is InMode's official website?

The official website for InMode is www.inmodemd.com.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.